Latest Market Developments in Antipsychotic Drugs Industry: Forecast 2025–2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_
_x000D_
#What Does the Forecast Indicate for the Antipsychotic Drugs Market From 2025 to 2029?#_x000D_
In recent times, the market size for phosphoinositide 3-kinase (PI3K) inhibitors has seen swift expansion. The market, which stood at $1.38 billion in 2024, is expected to rise to $1.56 billion in 2025, illustrating a compound annual growth rate (CAGR) of 12.8%. This growth during the historic period is largely due to the escalating occurrence of cancer, enhanced research on targeted therapies, approval of first-generation PI3K inhibitors by regulatory bodies, increased healthcare spending, and a rising number of clinical trials targeting hematologic malignancies._x000D_
_x000D_
The market for phosphoinositide 3-kinase (PI3K) inhibitors is likely to experience significant growth in the near future. It is projected to expand to “$2.55 billion by 2029, with a compound annual growth rate (CAGR) of 13.2%. The projected growth in the upcoming period can be credited to factors such as increased preference for combination treatments, the emergence of next-gen PI3K inhibitors with better safety measures, heightened investments in cancer R&D, extension of applications beyond just oncology, and the rising implementation of biomarkers for patient selection. Key trends anticipated during the forecast period involve a transition towards dual and pan-isoform PI3K inhibitors, a growing inclination towards oral drugs over intravenous options, a mounting focus on surpassing resistance mechanisms, increased adoption of artificial intelligence in pharmaceutical discovery, and an enlarging role of PI3K inhibitors in immunotherapy combinations._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=23474&type=smp_x000D_
_x000D_
#What Elements Are Contributing To Growth In The Antipsychotic Drugs Market?#_x000D_
The rise in mental health disorders is predicted to fuel the expansion of the antipsychotic drug market. Mental illnesses can significantly influence an individual’s thought processes, behavior, emotions, and overall mental health. These disorders can result from a variety of factors, including stress, societal expectations, inherited traits, chemical imbalances in the brain, developmental issues within the nervous system, and physical health problems. Antipsychotic medications work by modifying the functions of neurotransmitters, primarily dopamine and serotonin, to alleviate psychotic symptoms, stabilize emotions, and enhance cognitive and emotional performances. For example, a survey by the Substance Abuse and Mental Health Services Administration (SAMHSA), a US-based public health government agency, revealed that nearly 6% of adults over 18 years old, amounting to 15.4 million people, reported serious mental illness (SMI) in November 2023. Moreover, in September 2024, the Australian Institute of Health and Welfare projected that the number of people with dementia in Australia will more than double, from about 411,100 in 2023 to 849,300 by 2058, impacting about 315,500 men and 533,800 women. Consequently, the escalating incidence of mental health disorders is driving the growth of the antipsychotic drug market._x000D_
_x000D_
_x000D_
The phosphoinositide 3-kinase (pi3k) inhibitors market covered in this report is segmented – _x000D_
_x000D_
1) By Type Of Inhibitor: Isoform Selective Inhibitors, Pan-Phosphoinositide 3-Kinase (PI3K) Inhibitors, Dual Phosphoinositide 3-Kinase (PI3K) Or Mechanistic Target Of Rapamycin (mTOR) Inhibitors, Novel Targeted Inhibitors_x000D_
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel_x000D_
3) By Application Areas: Cancer Treatment, Metabolic Disorders, Autoimmune Diseases, Neurological Disorders_x000D_
4) By End User: Hospitals, Research Institutes, Pharmaceutical Companies, Contract Research Organizations (CROs)_x000D_
_x000D_
Subsegments:_x000D_
1) By Isoform Selective Inhibitors: Phosphoinositide 3-Kinase Alpha (PI3Ka), Phosphoinositide 3-Kinase Beta (PI3Kß), Phosphoinositide 3-Kinase Delta (PI3Kd), Phosphoinositide 3-Kinase Gamma (PI3K?)_x000D_
2) By Pan-Phosphoinositide 3-Kinase (PI3K) Inhibitors: Class I Phosphoinositide 3-Kinase (PI3K), Non-Isoform Specific Phosphoinositide 3-Kinase (PI3K), Phosphoinositide 3-Kinase Kinase Domain_x000D_
3) By Dual Phosphoinositide 3-Kinase (PI3K) Or Mechanistic Target of Rapamycin (mTOR) Inhibitors: Phosphoinositide 3-Kinase (PI3K) and Mechanistic Target of Rapamycin (mTOR) Inhibition, Adenosine Triphosphate-Competitive Dual Inhibitors, Allosteric Dual Inhibitors_x000D_
4) By Novel Targeted Inhibitors: Next-Generation Phosphoinositide 3-Kinase, Targeting Mutant Phosphoinositide 3-Kinase Isoforms, Autophagy Modulators, Checkpoint Inhibitors, Combination Therapies_x000D_
_x000D_
#What Future Market Trends Are Projected For The Antipsychotic Drugs Industry?#_x000D_
Leading entities in the phosphoinositide 3-kinase (PI3K) inhibitors market are centering their efforts on formulating novel solutions such as PI3K delta inhibitor treatments. This advanced approach is aimed at providing targeted intervention for disorders linked to abnormal phosphoinositide 3-kinase (PI3K) signaling. The PI3K delta inhibitor therapy obstructs the PI3K delta enzyme which is integral to immune cell signaling, leading to the reduction of inflammation, autoimmune reactions and specific blood cancers. An example of this occurred in March 2023, when the FDA, a regulatory body in the US, granted permission for Joenja (leniolisib) . This served as the inaugural treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in individuals 12 years old and beyond. The endorsement represented a significant landmark in precision therapies, introducing a method to tackle immune dysfunction triggered by genetic variations in the PIK3CD or PIK3R1 genes. The introduction of Joenja (leniolisib) not only broadens the medicinal reach of phosphoinositide 3-kinase (PI3K) inhibitors beyond the realm of cancer, but it also emphasizes the amplified dedication towards individualized treatments for rare immune disorders._x000D_
_x000D_
#Who Are The Key Contributors To Growth In The Antipsychotic Drugs Market?#_x000D_
Major companies operating in the phosphoinositide 3-kinase (PI3K) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline (GSK) Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences, Boehringer Ingelheim, Genentech Inc., Incyte Corporation, Exelixis, Kura Oncology, TG Therapeutics Inc., Verastem Oncology _x000D_
_x000D_
_x000D_
_x000D_
#Which Region Is Projected To Lead The Antipsychotic Drugs Market By 2025?#_x000D_
North America was the largest region in the phosphoinositide 3-kinase (PI3K) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phosphoinositide 3-kinase (PI3K) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=23474&type=smp_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
